Advertisement
Screener

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Future Amortization Expense, Year Three (Deprecated 2012-01-31)

2.8 / 5 stars · 68/120 Roast Me

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Future Amortization Expense, Year Three (Deprecated 2012-01-31)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Future Amortization Expense, Year Three (Deprecated 2012-01-31) of $11.10 million for the 12-month period ending 2012-12-29, per its 10-K filed 2013-02-27.

Discontinued › Expense Statement › Operating Expenses

us-gaap:FutureAmortizationExpenseYearThree · last filed 2013-02-27

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. future amortization expense, year three (deprecated 2012-01-31) for fiscal 2012 was $11.10M, a 5.48% decline from fiscal 2011.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. future amortization expense, year three (deprecated 2012-01-31) for fiscal 2011 was $11.74M.
Period endFuture Amortization Expense, Year Three (Deprecated 2012-01-31) 12 month
2012-12-29$11.10M
10-K · filed 2013-02-27
2011-12-31$11.74M
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71